EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD

Tae-Hwi Schwantes-An, Marco A Abreu, Brent A Neuschwander-Tetri, Jian Wang, Xiuqing Guo, Jingyi Tan, Robert A Hegele iD, Nicholas O Davidson, Luca Lotta, Niek Verweij, Katherine P Yates, Jerome I Rotter und 1 weitere

Liver International · 2026

DOI: 10.1111/liv.70486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2026. Verfasst von Tae-Hwi Schwantes-An und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Dyslipidemias, Hyperlipoproteinemia Type II. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Dyslipidemia is common in patients with MASLD, but the frequency and significance of inherited disorders of dyslipidemia are unclear. We investigated the prevalence and significance of pathogenic variants associated with selected monogenic disorders of dyslipidemia in 3358 patients with well‐characterised MASLD. Approach We identified clinically relevant variants in APOB , MTTP , PCSK9 , ANGPTL3 , LDLR and LDLRAP1 genes which can cause hypobetalipoproteinemia (HBL) and familial hypercholesterolemia (FH). Using ClinVar annotations as initial variant selection, we identified 2027 variants in those 6 genes which are reported as ‘pathogenic’ or ‘likely pathogenic’ (P/LP). We first assessed for the presence of P/LP variants in the study cohort and then investigated the effect of carrying P/LP variants on liver histology, by comparing ~4 matched controls for each APOB and LDLR carrier. As interpretative analyses, we also looked at the difference between liver enzymes, lipid measures and outcomes between the carriers and matched controls.

Results

Twenty‐two variants among these 2027 P/LP variants were present in 24 out of 3358 patients (12 ApoB , 10 LDLR , 1 ANGPTL3 and 1 MTTP variant carriers). Compared to controls, APOB carriers had higher steatosis grade (2.4 vs. 1.7, p ‐value 0.0028), higher NAFLD activity score (NAS) (4.9 vs. 3.8, p ‐value 0.04), and numerically higher but statistically not significant fibrosis stage (1.2 vs. 1.1, p ‐value 0.75) and ALT (87.4 vs. 58.1 U/L, p ‐value 0.06). Their LDL‐c (51 vs. 147.8 mg/dL, p ‐value 6.1E‐09) and triglycerides (91.5 vs. 160.6 mg/dL, p ‐value 2.8E‐03) were significantly lower. Compared to controls, LDLR carriers had numerically higher steatosis grade, NAS, fibrosis stage and LDL‐c levels, but these were not statistically different.

Conclusions

Monogenic disorders of dyslipidemia are rarely present in patients with MASLD and are sometimes associated with worse liver histology. Testing for these conditions may be considered on a case‐by‐case basis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasHyperlipoproteinemia Type IIHumansFemaleMaleReceptors, LDLProprotein Convertase 9Middle AgedAngiopoietin-Like Protein 3AdultAngiopoietin-like ProteinsAdaptor Proteins, Signal TransducingLiverCarrier ProteinsApolipoprotein B-100Case-Control StudiesHypobetalipoproteinemiasGenetic Predisposition to Disease

Stichwörter der Autor:innen

APOBLDLRMASLDhereditary dyslipidemiahistological progression

Substanzen

Receptors, LDLProprotein Convertase 9Angiopoietin-Like Protein 3ANGPTL3 protein, humanPCSK9 protein, humanmicrosomal triglyceride transfer proteinLDLRAP1 protein, humanAngiopoietin-like ProteinsAdaptor Proteins, Signal TransducingCarrier Proteins

Autor:innen und Institutionen

  • Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Division of Gastroenterology and Hepatology, Saint Louis University, St Louis, Missouri, USA.
  • Robarts Research Institute, Schulich School of Medicine & Dentistry, Western University, 1151 Richmond St, London, Ontario, Canada.
  • Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
  • Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

ORCID-Profile: Robert A Hegele

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Schwantes-An, T. H., Abreu, M. A., Neuschwander-Tetri, B. A., Wang, J., Guo, X., Tan, J., Hegele, R. A., Davidson, N. O., Lotta, L., Verweij, N., Yates, K. P., Rotter, J. I., & Chalasani, N. (2026). Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD. Liver International. https://doi.org/10.1111/liv.70486

Vancouver

Schwantes-An TH, Abreu MA, Neuschwander-Tetri BA, Wang J, Guo X, Tan J, et al. Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD. Liver International. 2026. doi:10.1111/liv.70486

BibTeX
@article{SchwantesAn2026,
  author = {Schwantes-An, Tae-Hwi and Abreu, Marco A and Neuschwander-Tetri, Brent A and Wang, Jian and Guo, Xiuqing and Tan, Jingyi and Hegele, Robert A and Davidson, Nicholas O and Lotta, Luca and Verweij, Niek and Yates, Katherine P and Rotter, Jerome I and Chalasani, Naga},
  title = {Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70486}
}
Kostenlos starten →